With a market cap of $149.1 billion, Amgen Inc. (AMGN) is renowned for its innovative human therapeutics across oncology, ...

Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ ... "Robust growth in sales and earnings throughout 2024 reflects the momentum of our business.

Negative contributors included Regeneron Pharmaceuticals, Amgen, and Vertex Pharmaceuticals, driven by competitive pressures and disappointing clinical trial results. New holdings include Halozyme ...

Global Data has revealed that the Top 20 Global Biopharmaceutical Companies have witnessed a 6 % growth in market ...

Amgen Inc. (NASDAQ:AMGN ... cutting-edge treatments. After fiscal Q4 2024, the company had 14 pharmaceuticals with annualizations of more than $1 billion each. Several of these are expected ...

BioMarin Pharmaceutical reported revenues of $747.3 million, up 15.6% year on year, outperforming analysts’ expectations by 4.8%. The business had a stunning quarter with a solid beat of analysts’ EPS ...

With a market cap of $149.1 billion, Amgen Inc. (AMGN ... reflecting a 3.9% increase from $19.84 in fiscal 2024. Analysts' consensus rating on AMGN stock is cautiously optimistic, with a ...